Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diltiazem's effect on ACT-541468 pharmacokinetics
NCT02526888Phase 1Completed
- Sponsor
- Idorsia
- Start
- Sep 2015
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of daridorexant in Insomnia (2 arms), sponsored by Idorsia. Primary endpoints: Maximum plasma concentration of ACT-541468, Time to reach Cmax of ACT-541468 in plasma and 1 more. Started Sep 2015; status: completed.
02
Drugs
daridorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT02526888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02526888.